Pharma News: Growing Legal Storm Over Semaglutide and Vision Loss
Novo Nordisk is confronting escalating legal pressure in the United States as more plaintiffs come forward alleging that its blockbuster semaglutide drugs—Ozempic, Wegovy and Saxenda—caused sudden and sometimes permanent blindness. A newly formed federal mass litigation now focuses exclusively on vision-related injuries, marking the second major legal battle involving these widely prescribed GLP-1 agonists. Eli Lilly’s Trulicity is also named in many of the cases, broadening the industry-wide scrutiny.
Lawsuits mount against Novo Nordisk as semaglutide drugs face deeper scrutiny for potential blindness risks.
Image Credit: Hastings Law Firm
This
Pharma News report highlights that concerns over optic nerve damage have rapidly shifted from isolated patient claims to a structured national litigation front.
Vision Loss Claims Gain Momentum
Central to the lawsuits is the allegation that semaglutide medications can trigger non-arteritic anterior ischemic optic neuropathy or NAION. Often described as an “eye stroke,” NAION stems from reduced blood flow to the optic nerve and can lead to abrupt, irreversible vision loss in one or both eyes. Published research in 2024 and 2025 identified a higher incidence of NAION among semaglutide users, especially those with type 2 diabetes, fueling public alarm and supporting the plaintiffs’ claims.
As of now, at least 30 federal lawsuits and more than 40 state-level suits have been filed, with additional cases expected as awareness grows. Many plaintiffs say Novo Nordisk and Eli Lilly failed to provide adequate warnings about the severity and likelihood of such vision-related complications.
Federal Panel Creates New MDL in Philadelphia
In December 2025, the U.S. Judicial Panel on Multidistrict Litigation approved the creation of a dedicated MDL in Philadelphia federal court. This proceeding will be overseen by U.S. District Judge Karen Marston, who also presides over the earlier MDL concerning gastrointestinal injuries such as gastroparesis and ileus. While the two litigations share scientific overlap, the court determined that distinct medical issues warranted separation.
Novo Nordisk and Eli Lilly had argued for merging the blindness claims into the existing GI-related MDL. Plaintiffs succeeded in convincing the panel that the optic neuropathy cases involve unique evidence, expert testimony and injury patterns.
Regulatory Actions and Global Ramifications
The European Medicines Agency has already acknowledged NAION as a “very rare” adverse effect of semaglutide—occurring in as many as one in 10000 users. The EMA directed Novo Nordisk to update safety labels and patient leaflets, and the company complied in EU markets. In Denmark, four individuals have r
eceived state-funded compensation for vision loss linked to semaglutide, offering further support for the growing body of claims.
Novo Nordisk maintains that the overall benefit-risk profile of semaglutide remains favorable. Nonetheless, the company faces years of litigation, with no major settlements expected before late 2027.
Broader Impact and Future Implications
The intensifying legal fight underscores widespread unease among patients and clinicians who depend on GLP-1 drugs for diabetes and weight management. With nearly one in four U.S. adults with diabetes using these medications, even rare complications quickly translate into significant public health concerns. The findings so far strongly suggest that semaglutide-associated optic nerve damage may be more widespread than initially believed, and the mounting lawsuits could reshape regulatory oversight, prescribing practices and patient monitoring requirements. As investigations continue, the medical community may be compelled to reassess long-term safety assumptions surrounding GLP-1 therapies and adopt far more aggressive risk-mitigation measures to safeguard vulnerable users.
Reference:
https://www.hastingsfirm.com/ozempic-vision-lawsuit-national-attorneys/
https://www.motleyrice.com/diabetes-lawsuits/ozempic
For the latest
Pharma News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/pharma-news
Share
Tweet
Share
